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Engaging Patients in Atrial Fibrillation
Management via Digital Health Technology:
The Impact of Tailored Messaging
TAMMY TOSCOS, phd,1 AMANDA COUPE, ba,1 SHAUNA WAGNER, rn, bsn,1 RYAN AHMED, ms,1
AMELIA ROEBUCK, bs,1 MINDY FLANAGAN, phd,1 MICHELLE DROUIN, phd,1
and MICHAEL MIRRO, md, facc, fhrs, faha, facp1
Parkview Mirro Center for Research and Innovation, Health Services and Informatics Research Department, Parkview
Health, Fort Wayne, IN 46845, USA
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ABSTRACT. Patients with atrial fibrillation (AF) demonstrate persistent knowledge gaps
regarding their condition and a substandard adherence to oral anticoagulant (OAC) medication,
which contribute to thromboembolic stroke and other clot-related complications. Tailored patient
education and medication reminders may help reduce these negative health outcomes. We sought
to improve disease knowledge and medication adherence among a sample of AF patients using tailored education and nudges. The intervention leveraged three digital health technologies: a patient
portal, an electronic-prescribing data feed, and a smart pill bottle. The content of the educational
messaging, nudges, and cadence were tailored according to findings from our user-centered design
studies and delivered via a patient portal (MyChart®; Epic Systems, Verona, WI, USA), with which
participants were familiar. In a six-month randomized controlled trial with parallel groups, we used
MyChart® to send educational messages and medication reminders according to a decision tree that
emerged from our prior user-centered design studies. The intervention group demonstrated higher
AF knowledge at study completion than the control group and more MyChart® logins throughout
the trial, suggesting intervention uptake. Women were more adherent than men and patients diagnosed more than one year ago were more adherent than those with more recent diagnoses. The intervention and control group adherence rates were 93.1% and 89.5%, respectively; intervention effect
was moderated by age, medication type, and prior MyChart® use. Within the intervention group,
younger patients, those taking once-daily rivaroxaban, and those who were less active MyChart®
users prior to the study benefited relative to their control group counterparts. Tailored educational
and reminder messages contributed to increased adherence and disease knowledge among AF
patients, though certain patient characteristics moderated the intervention’s effectiveness. Technology-based health interventions can be useful for older adults with effective tailoring and training.
KEYWORDS. Atrial fibrillation, consumer health informatics, digital health, medication
adherence, tailored messaging.

Introduction
AF is a common chronic cardiac arrhythmia that is
increasing with the growing aging population and
which is associated with a least a four- to fivefold rise
in stroke risk.1 Although oral anticoagulants (OACs)
decrease AF patients’ stroke risk, more than half of
these individuals do not take them as prescribed,2 due
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in part to a lack of knowledge about their condition and
treatment.3,4 In recent years, the development of direct
OACs (DOACs), which require less monitoring and
have a shorter half-life than warfarin, has prompted
additional adherence concerns and rendered adher
ence more crucial.5,6 As such, researchers have called
for improved patient education to lessen this treatment
gap.7,8
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Although multiple individual and systemic factors contribute to medication adherence,9 education also plays
a key role.10,11 AF patients desire more education than
they are currently given,4,12 while persistent knowledge gaps and low adherence illustrate that education
should be a continual process in line with AF’s chronic
nature.3,4,13,14 Current education may also not be appropriately tailored to patient needs or health literacy, even
though this is important for understanding, application,
and making behavior changes.15–18 As such, advances
in technology, such as electronic health record (EHR)
patient portals, provide an enhanced means of continual patient–provider communication and present an
opportunity to tailor the content of such communication, for example by using information available within
the EHR.19

tailored educational messages via an EHR patient portal
(MyChart®; Epic Systems, Verona, WI, USA). In the present study, we implemented this intervention, hypothesizing that it would increase OAC adherence and AF
knowledge.

Some prior research has examined educational interventions for AF patients. One-time educational sessions
have been associated with higher warfarin adherence
at six months20 and lower AF-related complications at
one year.21 Other studies have assessed the impact of
continual education interventions, including a combined health education and reminder calendar model
that resulted in increased dabigatran adherence across
one year22 and a smartphone app with clinical decision support and education that was found to increase
adherence, AF knowledge, quality of life, and OAC
satisfaction at one and three months.23 These studies,
combined, illustrate the potential for increasing adherence and other positive outcomes via AF patient education. However, we identified an opportunity to present a continual education intervention via technology
that this older patient population may already use in
a health care context (ie, EHR patient portal) as well as
to tailor this intervention based on patient preferences
and characteristics.

Clinic staff and research team members identified
789 potential participants via a chart review, of which
703 were contacted by email, MyChart® message, letter,
and/or telephone to screen for inclusion/exclusion criteria not available in the EHR. Recruitment was stratified to
include equal numbers of individuals using DOACs (ie,
rivaroxaban, apixaban, and edoxaban) and warfarin in
both the intervention and control groups. Patients taking
dabigatran could not be enrolled; we used an electronic
pill bottle to track dosing and these pills must be stored in
their original container. The enrollment target was 80 participants per group based on initial power calculations
(power: 0.80; significance: 0.05). Ultimately, allowing for
20% attrition, a total of 160 patients were enrolled. Group
assignment was randomized but not blinded. See Figure
1 for a flowchart of the participant selection process.

Methods
Participants and setting
Participants included adult outpatient cardiology
patients at a Midwestern United States hospital who had
been diagnosed with nonvalvular AF and prescribed an
OAC. Participants were also required to have access to a
computer and the Internet as well as to have a MyChart®
account or report the willingness to create one.

Present study objectives
In response to the opportunities identified in extant literature, we designed a multiphase study. In the first phase,
as reported in our prior work,4 we used focus groups
and online surveys to elicit preferences from AF patients
regarding content, timing, and delivery of AF-related
educational information and reminders. Based on these
preferences, we then created an algorithm to deliver
All authors report the receipt of grants from Janssen Scientific
Affairs, LLC during the conduct of the study. Dr. Mirro additionally reports the receipt of personal fees from Zoll Medical, personal
fees and other funding from iRhythm, other funding from MURJ,
and other funding from Viscardia outside the scope of the submitted
work. This research was funded by a grant from Janssen Scientific
Affairs, LLC, which approved this manuscript and its submission
for publication (research funding agreement: ICD#870276; protocol
no. 39039039AFL4007).
Manuscript received March 3, 2020, Final version accepted April 17,
2020.
Address correspondence to: Amanda Coupe, BA, Parkview Mirro
Center for Research and Innovation, 10622 Parkview Plaza Dr., Fort
Wayne, IN 46845, USA. Email: amanda.coupe@parkview.com.
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Figure 1: Study Consolidated Standards of Reporting Trials
diagram. Process of participant screening, enrollment, group
assignment, attrition, and inclusion in analyses.
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Initially, participants met privately with a research team
member for approximately one hour to provide written
informed consent and complete surveys and training. Participants were compensated US$50 at both enrollment and
completion on a reloadable debit card. Recruitment began
in June 2017; the study concluded in November 2018. All
study procedures were approved by the Parkview Health
System Institutional Review Board and all procedures were
performed in accordance with the standards established by
the 1964 Declaration of Helsinki and its later amendments.

Data collection and measures

Table 1: Participant Characteristics
Characteristic Number
Valid
Gender

160

Age (years)

160

Race

154

Survey data
Survey data were collected at baseline and exit. Paper-based
surveys were administered to all participants during enrollment meetings. Paper surveys were mailed to the control
group upon trial period completion; intervention group
participants received links to secure, Health Insurance
Portability and Accountability Act (HIPAA)-compliant
web-based surveys hosted on SurveyMonkey (SVMK Inc.,
San Mateo, CA, USA) in their final study-related message.
Participant characteristics. Various demographic information was collected, including age, gender, race, income,
employment, education level, and time since diagnosis
(Table 1).
Patient engagement. Patient engagement was assessed
with the Patient Activation Measure (PAM),24,25 a validated self-report survey that operationalizes patient
activation into four developmental stages: (1) believes
importance of the patient role, (2) has confidence and
the health-related knowledge required to act, (3) takes
health-related actions, and (4) maintains actions despite
stress. It included 10 items with a four-point Likert-type
response set (1 = disagree strongly to 4 = agree strongly)
that were scored and categorized into levels 1 through 4.
Health literacy and knowledge of atrial fibrillation.
Health literacy was assessed using the Newest Vital
Sign (NVS) assessment,26 a nutrition label with six interpretive questions. The number of correct responses was
totaled; four or more correct answers was considered
to suggest the respondent had adequate health literacy.
The AF Knowledge Scale27 included 11 items testing
for the understanding of AF and its treatment. Correct
responses were totaled. Potential scores ranged from zero
to 11 points; we evenly divided them into a simple low/
medium/high bracket (0–3, 4–7, or 8–11 points) to categorize the level of knowledge as such.

Intervention uptake
MyChart® logins for the six months prior to and after
study initiation were captured and dichotomized as low
(0–12 logins) and high (13+ logins) based on the median
(12 logins).

Employment
status

158

Education
level

154

Annual
income

149

Household
occupants

158

PAM

155

Health literacy 158
(NVS)

Category

%

Female
Male
41–50
51–60
61–70
71–80
81–90
91–100
White or Caucasian
Asian
Black or African-American
Hispanic or Latino
American Indian or Alaska
Native
Native Hawaiian or other
Pacific Islander
Employed full-time
Employed part-time
Unemployed
Disabled/unable to work
Retired
Did not graduate high school
High-school graduate/GED
Trade/some college
College graduate
Postgraduate degree

37.50
62.50
1.25
11.25
31.25
46.25
9.38
0.63
99.4
0.65
0
0
0

< $20,000
$20,000–40,000
$40,001–60,000
$60,001–80,000
$80,001–100,000
> $100,000
Lives alone
Lives with a spouse/partner
Lives with a family member
Lives with a friend
Level 1
Level 2
Level 3
Level 4
High likelihood of limited
literacy
Possibility of limited literacy
Adequate literacy

0
13.92
5.06
1.90
5.70
73.42
3.25
21.43
29.87
25.32
20.13
5.37
22.82
24.16
24.83
9.40
13.42
16.46
77.85
5.06
0.63
10.32
29.68
49.68
10.32
6.33
16.46
77.22

NVS: Newest Vital Sign; PAM: Patient Activation Measure.

Medication adherence
Medication adherence was tracked using AdhereTech’s
Wireless Smart Pill Bottle (AdhereTech, New York, NY,
USA), a HIPAA-compliant, Food and Drug Administration
(FDA)-registered class I medical device that sends notifications when a user opens or fails to open the lid, based
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Figure 2: Intervention with sample message. Participants received educational and reminder messages based on information
gathered from multiple digital health technologies. Example reminder text is shown, along with example educational topics
and images of a sample educational message and its corresponding video.

on dose schedule. In real-world use, these data would go
to the user; however, for study purposes, they were sent
to the study team, who then sent reminder messages to
the intervention group (detailed below). Aside from using
the smart pill bottle to store and dispense medication, the
control group continued with standard care.
Participants were instructed to inform study staff of
prescription/dosing changes as well as any temporary
discontinuation of either their OAC or the bottle for any
reason (eg, hospitalization, travel). For these situations,
prescribed doses were adjusted accordingly for analyses.

Intervention
Participants in the intervention group were sent educational messages and reminders via MyChart® throughout the six-month trial. See Figures 2 and 3 for more
information.

Reminders

Educational messages
Based on patient content preferences identified previously,4 the research team created 24 educational messages,
using content from the American College of Cardiology’s
patient education site, Cardiosmart (www.cardiosmart.
org). Additionally, the study team created 14 videos featuring short interviews with four cardiologists and one
pharmacist discussing topics surrounding AF and anticoagulation, together with patient testimonials; links to
these videos were included in 14 corresponding messages.
4212

Figure 3: Messaging algorithm. Educational messages (blue)
were tailored based on anticoagulant and time since diagnosis. Event-specific reminders (yellow) were sent when participants missed either anticoagulant doses or prescription
refills.

Participants were sent a medication-specific reminder
message upon missing one DOAC dose or two warfarin
doses, as recorded by the bottle, with a follow-up message also sent upon missing a second DOAC dose or two
additional warfarin doses. These messages included a
reminder of the importance of OACs in stroke prevention, a suggestion to call the doctor about side effects or
refills, and a prompt to email the study coordinator about
bottle issues or routine changes that could cause inaccurate recordings. Participants received similar messages if
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they opened their bottle two or four extra times (depending on the medication being used) in one week.
SureScripts electronic prescribing information was used
to track pharmacy refills. Participants were sent reminder
messages upon being one week overdue for a refill, with
a follow-up notice sent when two weeks overdue. These
messages included the same suggestion to call one’s doctor with concerns and to notify the study team of routine
changes or data inaccuracies (eg, receiving medication
samples from their provider in lieu of renewing their
prescription).

Data analysis
Descriptive statistics were calculated for all measures,
including means and standard deviations (SDs) for continuous variables and frequencies for categorical variables. The intervention was hypothesized to impact
medication adherence; this was tested using generalized
linear models. For these models, medication adherence
was represented as the number of doses taken as a proportion of the prescribed number of doses. The rate of
adherence was estimated in a generalized linear model
with Poisson distribution using the log of total prescribed
doses as an offset term in the linear predictor. A generalized linear model was tested that included (1) age, gender, employment status, income, education level, and
time since diagnosis; (2) baseline PAM, AF knowledge,
and NVS results; and (3) MyChart® use predicting medication adherence. These predictors were initially tested
as main effects in separate models. Subsequently, for each
model, the study group and interactions between each
predictor and study group variable were entered, testing
whether predictors moderated the effect of intervention
on adherence. Participant OAC medication was included
in all models as it was a stratification variable for sample
selection (1 = warfarin, 2 = rivaroxaban, 3 = apixaban).
The set of predictors and interaction terms that were significant were included in one combined model and significant effects were retained. For comparison, a negative
binomial distribution was also used to estimate models.
However, the model fit statistics [deviance and Pearson’s
chi-squared (χ2) test] were not meaningfully improved;
therefore, results generated using a Poisson distribution
are presented.
As a check on intervention uptake, the following
measures corresponding to the expected intervention
impacts were tested for differences between study
groups: (1) number of MyChart® patient portal logins
and (2) AF knowledge. The number of MyChart® logins
during the study period was tested for relation to the
study group, prior MyChart® logins, and participant
characteristics using a generalized linear model. Also,
a generalized linear model assessed whether AF knowledge at study completion was related to the study
group, baseline AF knowledge, or participant characteristics. Data analysis was completed using the SAS
version 9.4 software program (SAS Institute, Cary, NC,
USA).

Results
In total, 160 participants were enrolled (n = 80 intervention and n = 80 control participants; 62.5% male; 99.4%
white; mean ± SD age: 71.1 ± 8.5 years) (Table 1). No
significant demographic differences emerged between
the groups. See Figure 1 for details related to participant
attrition and inclusion in the analyses.

Intervention uptake and knowledge of atrial
fibrillation
Prior to the study, each group had similar MyChart®
login activity (mean ± SD: 18.6 ± 20.8 times for the control
group; mean ± SD: 17.8 ± 18.8 times for the intervention
group). However, during the study period, the rates differed significantly (χ2 = 62.04; p < 0.0001), with the intervention group (mean ± SD: 42.7 ± 37.0 times) conducting
significantly more logins than the control group (mean
± SD: 15.9 ± 16.0 times). Additionally, the intervention
group demonstrated greater AF knowledge at study completion than the control group when controlling for AF
knowledge at baseline (χ2 = 6.66; p = 0.0099).

Intervention impacts on medication adherence
As shown in Table 2, the final model included gender,
age, time since diagnosis, medication type, prestudy
MyChart® use, and study group. Males presented lower
rates of medication adherence relative to females, while
those diagnosed with AF more than one year prior to the
study showed greater adherence to medication use than
those who received their diagnoses more recently.
Overall, the intervention and control groups demonstrated medication adherence rates of 93.1% and 89.5%,
respectively. In the main effects–only model, the intervention had a marginally significant effect on medication
adherence (p = 0.08) (Table 3). The moderating effects of
age, medication type, and prestudy MyChart® use are
illustrated in Table 4, which offers predicted values for
medication adherence devised from the final fitted model.
The moderated effect of intervention by age reveals that
younger participants benefited more from the intervention in terms of adherence. Specifically, intervention participants at the mean age (71 years; z = −3.02; p = 0.003)
and one SD below (63 years; z = −4.71; p < 0.0001) showed
higher adherence relative to their control counterparts,
whereas, at one SD above the mean age (79 years), there
were no differences between the study groups. Type of
medication moderated the effect of the intervention such
that participants taking rivaroxaban had significantly
higher adherence (z = −3.20; p = 0.001) in the intervention
group than the control group; no differences in adherence emerged for other OAC types. Finally, participants
with low MyChart® use prior to the study benefited more
from the intervention, exhibiting higher adherence in
comparison with among their control group counterparts (z = −3.61; p = 0.0003); this difference was not found
among those with high MyChart® use prior to the study.
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Table 2: Summary Results from Generalized Linear Modeling Predicting Medication
Adherence (n = 155)
Parameter

Estimate Standard
Wald 95%
Error
Confidence Limits

p > χ2

Intercept
Male (versus female)
Age

−0.12
−0.03
0.0001

0.07
0.01
0.0009

−0.25
−0.05
−0.002

0.008
−0.01
0.002

0.07
0.0047
0.90

AF diagnosis at > 1 year (versus < 1 year)
Warfarin (versus apixaban)
Rivaroxaban (versus apixaban)
Low MyChart use (versus high)
Control (versus intervention)

0.06

0.02

0.03

0.10

0.02
0.04
0.01
−0.32

0.02
0.02
0.02
0.09

−0.02
−0.002
−0.02
−0.50

0.05
0.09
0.04
−0.13

< 0.0001
0.41
0.06
0.45
0.0006

Study group × age

0.005

0.001

0.002

0.007

0.0002

Study group × education (warfarin)

−0.02

0.02

−0.07

0.03

0.37

Study group × medication (rivaroxaban) −0.10

0.03

−0.17

−0.03

0.0033

Study group × MyChart use

0.02

−0.09

−0.002 0.04

−0.05

Goodness of Fit

Value

Deviance
Pearson’s chi-squared

207.52
198.37

DF
143
143

Value/DF
1.45
1.39

AF: atrial fibrillation; DF: degrees of freedom.
Table 3: Summary Results from Main Effects–only Generalized Linear Modeling
Predicting Medication Adherence (n = 155)
Parameter

Estimate Standard
Error

Wald 95%
Confidence
Limits

p > χ2

Intercept

−0.25

0.05

−0.35

Male (versus female)

−0.03

0.01

−0.05

< 0.001
−0.005 0.02

Age

0.002

0.0006

0.001

0.004

< 0.001

AF diagnosis at > 1 year (versus < 1 year)
Warfarin (versus apixaban)
Rivaroxaban (versus apixaban)
Low MyChart use (versus high)
Control (versus intervention)

0.06

0.02

0.02

0.09

0.01
0.004
−0.01
−0.02

0.01
0.02
0.01
0.01

−0.01
−0.03
−0.03
−0.04

0.03
0.04
0.01
0.002

< 0.001
0.44
0.83
0.25
0.08

Goodness of Fit
Deviance
Pearson’s chi-squared

Value
235.35
219.74

DF
147
147

−0.16

Value/DF
1.60
1.49

AF: atrial fibrillation; DF: degrees of freedom.

Discussion
Our findings demonstrate positive outcomes of delivering a tailored messaging intervention to patients with AF.
Though similar to prior work,20–23 our study focused on
continued education via a health technology approach
(EHR patient portal) with which patients were familiar.
Relative to the control group, the intervention group
participants logged into MyChart® significantly more
often during the study period and had higher AF knowledge scale scores at exit. Although we cannot isolate the
impact of the educational messages versus the medication reminders on adherence, the comparatively higher
level of AF knowledge in the intervention group at exit
suggests participants were reading and retaining the
information they were given.
4214

We also identified other variables related to adherence,
including patient characteristics that moderated the effect
of the intervention. The older adult participants in our
sample (mean age: 71.1 years) were overall successfully
engaged by this technology-based intervention. However, intervention group participants at the mean age and
one SD below (ie, 71 and 63 years) showed higher adherence than their control group counterparts, while this
effect disappeared by one SD above the mean (79 years).
This underscores the importance of considering age differences and, potentially, individuals’ varied technological familiarity within the older adult age group and modifying the training accordingly.
In contrast with prior research suggesting that adherence decreases across time since diagnosis with a chronic
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Table 4: Predicted Values from Generalized Linear Modeling Predicting
Medication Adherence (n = 155)
Parameter
Gender
Male
Female
Age
63 years
71 years
79 years
AF diagnosis

Predicted
Standard
Value
Error of Mean

χ2

p > χ2

0.0048

89.8
92.8

0.009
0.01

7.97

89.4
91.3
93.1

0.009
0.008
0.009

14.92 0.0001

< 1 year
> 1 year
Medication
Warfarin
Rivaroxaban

88.4

0.007

15.38 < 0.0001

94.3

0.014

91.8
90.7

0.01
0.01

Apixaban
MyChart use
Low
High
Study group

91.4

0.009

90.8
91.8

Control
Intervention

0.45

0.80

0.009
0.009

0.97

0.32

89.5

0.01

16.58 < 0.0001

93.1

0.009

Control × 63 years

86.0

0.01

Control × 71 years

89.5

0.01

Control × 79 years

93.0

0.01

Intervention × 63 years

93.0

0.01

Intervention × 71 years

93.1

0.009

Intervention × 79 years

93.2

0.01

Control × warfarin

90.9

0.01

Control × rivaroxaban

86.3

0.02

Control × apixaban

91.5

0.01

Intervention × warfarin

92.7

0.01

Intervention × rivaroxaban 95.3

0.02

Intervention × apixaban

91.3

0.01

Control × low use

88.0

0.01

Control × high use

91.0

0.01

Intervention × low use

93.6

0.01

Intervention × high use

92.5

0.01

Study group × age:

13.36 0.0002

Study group × medication

Study Group × MyChart use

8.68

0.01

4.21

0.04

AF = atrial fibrillation.

condition,28 patients diagnosed more than one year prior
to the study demonstrated greater adherence than those
diagnosed more recently. This could be due to lived experiences, wherein patients diagnosed longer may have
had more time to establish a routine, have had more
contact with the health system, or have experienced an
AF-related complication that motivated adherence; prior
research suggests that higher-risk AF patients maintain
higher adherence rates9,29 for these reasons.6 Still, this
suggests an opportunity to tailor interventions to better

engage newly-diagnosed AF patients, who often initially
feel overwhelmed with information—another reason
patients with recent diagnoses may have exhibited lower
adherence.4
Additionally, as seen in some prior research,6 women
demonstrated higher adherence rates than men. Lastly,
we noted that patients taking rivaroxaban demonstrated
greater adherence than those taking warfarin or apixaban, possibly because of the former’s once-daily dosing
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regimen.30 This illustrates the importance of considering
medication type and dosing regimen when designing

interventions to increase OAC adherence and evaluating
their effectiveness.

Limitations and future directions
Considered together, our outcomes and participant
demographics suggest the presence of a potential volunteer bias and/or ceiling effect. Both the intervention and
control groups demonstrated much higher OAC adherence rates than what is often reported among AF patient
samples (93.1% and 89.5%, respectively, versus as low as
50%)2 and this discrepancy has been discussed in prior
work.31 Perhaps, in a related fashion, the main effect of
this intervention on medication adherence was not statistically significant. However, the intervention did show
effects for participants with specific characteristics, providing a framework for future research.
The study sample was overwhelmingly white (99.4%)
and educated (only 3.25% did not have a high school
diploma/GED), limiting generalizability. AF patients
with higher levels of information discomfort are less
adherent16 and those with less education may have more
negative attitudes toward health care32; these patients
may be less likely to have volunteered for the study.
Future research could attempt to limit volunteer bias
and include a more ethnically and educationally diverse
patient population by implementing a similar intervention into standard care.
Our sample also likely had higher health engagement
and technological familiarity than the average AF patient,
as patients without computer or Internet access and those
who did not have or were unwilling to create a MyChart®
account were not included in this study.33 Relatedly, intervention participants with high MyChart® usage prior to
the study did not benefit relative to their control group
counterparts, while less active users did, suggesting a
potential ceiling effect.
As with nearly all methods of tracking medication adherence, there is some degree of accuracy limitation. We combined the smart pill bottle data with self-reports regarding events like medication holds or schedule disruptions
to correct as many bottle-related inaccuracies as possible.
Additionally, due to our use of the aforementioned bottle,
we were unable to include patients taking dabigatran, as
this medication must be stored in its original container.
Further evaluation of the smart pill bottle’s research utility is detailed in our other work34 and the development
of adherence technologies remains an important area of
exploration.
We included a link to an online postsurvey in the final
study-related MyChart® message sent to intervention group participants. Meanwhile, we mailed paperbased surveys to the control group, who had not been
contacted via MyChart® during the study; we felt
this would be a more reliable means of contact. These
4216

different administration methods are linked with group
membership; thus, any related effect cannot be separated.
Lastly, although this was not within the intended scope
of the present study, we recognize that clinical outcomes
(eg, lower hospitalization rates, less thromboembolic
events) are an important consideration when gauging the
efficacy of interventions for medication adherence among
AF patients; future research should explore this when
building upon these initial findings.

Conclusions
We present a framework for a tailored messaging intervention for AF patients taking OACs. We demonstrated
the potential of combining three digital health technologies (patient portal, an electronic prescribing data feed,
and a smart pill bottle) to deliver tailored educational
messages and nudges that were designed in partnership
with patients living with AF. Those who received educational messages and time-sensitive reminders through the
study intervention demonstrated greater AF knowledge
and higher rates of accessing the patient portal than those
who did not. Intervention group participants with certain
characteristics (eg, younger age, lower prestudy patient
portal use, once-daily dose OAC medication) showed
better OAC adherence than their control group counterparts and there was a nonstatistically significant trend
toward increased adherence in the intervention group
overall. Given the prevalence and severity of AF, coupled
with persistent AF knowledge gaps despite efforts being
made toward improving patient education, our findings
underscore the importance and interrelated nature of
health education and medication adherence. While our
findings demonstrate the efficacy of a high-fidelity prototype technology solution for AF education and OAC
reminder intervention within a relatively homogenous
study population, future research should focus on refining tailored messaging and context-sensitive delivery
through a user-centered design approach that includes
individuals of a more diverse racial, educational, and
socioeconomic background.
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